- $11.47m
- $9.42m
- $2.29m
Brief: Femasys Achieves Australian & New Zealand Regulatory Approvals For Femaseed For First-Line Infertility Treatment And Femvue Diagnostic
Brief: Femasys announces European Approval for Fembloc®, First Non-Surgical Permanent Birth Control
Brief: Femasys Announces Pricing Of Underwritten Public Offering And Concurrent Private Placement With Gross Proceeds Of $4.5 Million
Brief: Femasys Announces Proposed Public Offering Of Common Stock And Concurrent Private Placement
Brief: Femasys Inc. FY EPS USD -0.85
Brief: Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
Brief: Femasys Announces Issued U.S. Patent Covering FemBloc Device For Female Permanent Birth Control
Brief: Femasys Secures Strategic Distribution Partnerships For Commercialization Of FemaSeed For Over $1.3 Mln In Spanish Market
Brief: Femasys Announces CE Mark And Canadian Approval For Femvue® Mini
U.S. RESEARCH ROUNDUP-Agenus, Guardant Health, Zoetis
Brief: Femasys Completes First In-Office Commercial Procedure With FDA-Cleared FemaSeed Infertility Solution
Brief: Femasys Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center
Brief: Femasys Completes Enrollment Of Femaseed Pivotal Trial In Support Of Commercial Launch
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Femasys Received Notice From Nasdaq Informing Co It Has Regained Compliance With Nasdaq’S Listing Rule
Brief: Femasys Inc. Regains Compliance With Nasdaq Listing Requirements
U.S. RESEARCH ROUNDUP-Apollo Global Management, Draftkings, TFI International
Femasys gains on FDA clearance to market its infertility treatment